TLN-58, an Additional hCAP18 Processing Form, Found in the Lesion Vesicle of Palmoplantar Pustulosis in the Skin.
Murakami. Masamoto M; Kameda. Kenji K; Tsumoto. Hiroki H; Tsuda. Teruko T; Masuda. Kana K; Utsunomiya. Ryo R; Mori. Hideki H; Miura. Yuri Y; Sayama. Koji K
Key Findings
- TLN‑58 is a newly identified 7 kDa fragment of human cathelicidin‑18/LL‑37 found in PPP skin lesions
- TLN‑58 stimulates inflammatory cytokine production (IL‑17C, IL‑8, IL‑23, IL‑1α, IL‑1β) in normal keratinocytes
- TLN‑58 retains antibacterial activity against Staphylococcus aureus, Staphylococcus epidermis, and group A Streptococcus, similar to LL‑37
Practical Outcomes
- For most biohackers, this finding has limited direct use. It suggests that LL‑37‑derived peptides can both fight bacteria and provoke skin inflammation, so any DIY topical or supplement use of LL‑37 should consider potential irritation or inflammatory side‑effects.
Summary
Researchers discovered a new 7 kDa fragment of the skin antimicrobial peptide LL‑37, called TLN‑58, in lesions of a skin condition called palmoplantar pustulosis. This fragment can trigger inflammation in skin cells and also kills common bacteria, much like the original LL‑37 peptide.
Abstract
We previously reported that the early vesicle of the palmoplantar pustulosis (PPP) vesicle originated from eccrine sweat in the acrosyringium and that the PPP vesicle contains the antimicrobial peptide human cathelicidin-18/LL-37. The concentration of LL-37 was sufficient to induce the subsequent inflammation in lesions and human keratinocytes, and the PPP vesicles contained additional small fragments of human cathelicidin-18, of approximately 7 kDa, which have not been identified. The aim of the present study was to clarify the additional processed forms found in PPP vesicles and their physiological effects on normal keratinocytes and sweat gland cells. Lesional PPP vesicles were collected from PPP patients, and endogenous human cathelicidin-18/LL-37 was depleted using a LL-37 antibody affinity column. A designed recombinant human cathelicidin-18 peptide was prepared and incubated with the depleted PPP vesicle fluid to confirm the additional processed form. In-gel digestion analysis and protein sequencing confirmed the additional form as TLN-58. TLN-58 up-regulated IL-17C, IL-8, IL-23, IL-1α, and IL-1β mRNA and protein expression in normal human keratinocytes and also showed antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis, and group A Streptococcus species, similar to LL-37. This additional form could be involved in the continued inflammation in PPP lesions.
Study Information
pubmed
2016
2016-10-19T00:00:00.000Z
10.1016/j.jid.2016.07.044
23
39